Ipsen has further Inspiration with haemophilia portfolio
This article was originally published in Scrip
Executive Summary
Ipsen and Inspiration Biopharmaceuticals have expanded their partnership in preparation for the commercial launch of Inspiration's haemophilia product portfolio in Europe and reiterated plans to file a marketing authorisation application with the European Medicines Agency (EMA) for one such drug, IB1001, by the end of this year.